Andrew Bellinger - 28 Oct 2022 Form 4 Insider Report for Verve Therapeutics, Inc. (VERV)

Role: CSO & CMO
Signature: /s/ Andrew Ashe, Attorney-in-Fact for Andrew Bellinger
Issuer symbol: VERV
Transactions as of: 28 Oct 2022
Net transactions value: -$384,200
Form type: 4
Filing time: 01 Nov 2022, 17:00:14 UTC
Previous filing: 27 Sep 2022
Next filing: 02 Dec 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VERV	Common Stock	Options Exercise	$14,800	+10,000	+151%	$1.48^*	16,629	28 Oct 2022	Direct
transaction	VERV	Common Stock	Sale	$399,000	-10,000	-60%	$39.90	6,629	28 Oct 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VERV	Stock Option (right to buy)	Options Exercise	$0	-10,000	-10%	$0.000000	86,995	28 Oct 2022	Common Stock	10,000	$1.48	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 17, 2022.
F2	The remaining shares underlying this option, which was granted on September 17, 2019, vest in equal monthly installments until October 1, 2023.